18. TREATMENT OF FRACTURE NON-UNION USING RECOMBINANT BMP-7: SINGLE CENTRE EXPERIENCE

Abstract

Purpose: To analyse the results of the use of Recombinant Bone Morphogenic Protein (BMP-7) for treatment of fracture nonunions at our institution.

Method: From 2001 to 2006, 23 patients with fracture non-union were treated with BMP-7 for bone healing. There were 14 male and nine females. The mean age of patients was 45 years (Range 21–76 yrs). There were 11 femoral, nine tibial and three humerus fractures. There were four open injuries. The average number of operations before BMP-7 insertion was 2.5 (Range 0–6). The mean time between the injury and BMP insertion was 52 months (Range 5–312). Nine (40%) patients had previous autologous bone graft inserted without union. 4 patients had BMP-7 insertion on its own. In another 4 patients it was mixed with allograft. In the rest of 15 patients BMP-7 was mixed with autologous bone graft. 2 patients needed BMP-7 insertion on 2 separate occasions. In all except 1 patient the original fixation of the fracture had to be revised using various appropriate methods.

Results: All the fracture went on to unite within an average of seven months (Range 4–16). There were no complications from the use of BMP-7.

Conclusion: Use of recombinant BMP-7, bone graft and stable fixation lead to fracture union in all our patients. We believe that the use of BMP-7 improved the chances of fracture healing in persistent non-unions and it is safe and easy to use.